AR032628A1 - Compuesto polimorfo de 1-{6-etoxi-5-[3-etil-6,7-dihidro-2-(2-metoxietil)-7-oxo-2h-pirazolo[4,3-d]pirimidin-5-il]-3-piridilsulfonil}-4-etilpiperazina - Google Patents

Compuesto polimorfo de 1-{6-etoxi-5-[3-etil-6,7-dihidro-2-(2-metoxietil)-7-oxo-2h-pirazolo[4,3-d]pirimidin-5-il]-3-piridilsulfonil}-4-etilpiperazina

Info

Publication number
AR032628A1
AR032628A1 ARP010103576A ARP010103576A AR032628A1 AR 032628 A1 AR032628 A1 AR 032628A1 AR P010103576 A ARP010103576 A AR P010103576A AR P010103576 A ARP010103576 A AR P010103576A AR 032628 A1 AR032628 A1 AR 032628A1
Authority
AR
Argentina
Prior art keywords
dihydro
oxo
piridilsulfonil
etilpiperazina
metoxyethyl
Prior art date
Application number
ARP010103576A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR032628A1 publication Critical patent/AR032628A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
ARP010103576A 2000-07-28 2001-07-26 Compuesto polimorfo de 1-{6-etoxi-5-[3-etil-6,7-dihidro-2-(2-metoxietil)-7-oxo-2h-pirazolo[4,3-d]pirimidin-5-il]-3-piridilsulfonil}-4-etilpiperazina AR032628A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
AR032628A1 true AR032628A1 (es) 2003-11-19

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103576A AR032628A1 (es) 2000-07-28 2001-07-26 Compuesto polimorfo de 1-{6-etoxi-5-[3-etil-6,7-dihidro-2-(2-metoxietil)-7-oxo-2h-pirazolo[4,3-d]pirimidin-5-il]-3-piridilsulfonil}-4-etilpiperazina

Country Status (45)

Country Link
EP (1) EP1305314B1 (enExample)
JP (1) JP2004505087A (enExample)
KR (1) KR100457937B1 (enExample)
CN (1) CN1207297C (enExample)
AP (1) AP1400A (enExample)
AR (1) AR032628A1 (enExample)
AT (1) ATE286901T1 (enExample)
AU (2) AU2001272690B2 (enExample)
BG (1) BG107266A (enExample)
BR (1) BR0112734A (enExample)
CA (1) CA2417264C (enExample)
CZ (1) CZ2003126A3 (enExample)
DE (1) DE60108398T2 (enExample)
DO (1) DOP2001000217A (enExample)
DZ (1) DZ3364A1 (enExample)
EA (1) EA004681B1 (enExample)
EC (1) ECSP034454A (enExample)
EE (1) EE200300045A (enExample)
ES (1) ES2231521T3 (enExample)
GE (1) GEP20053494B (enExample)
HR (1) HRP20030061A2 (enExample)
HU (1) HUP0302982A3 (enExample)
IL (1) IL153226A0 (enExample)
IN (1) IN2002MU01649A (enExample)
IS (1) IS6626A (enExample)
MA (1) MA26931A1 (enExample)
MX (1) MX233602B (enExample)
MY (1) MY117831A (enExample)
NO (1) NO324220B1 (enExample)
NZ (1) NZ523226A (enExample)
OA (1) OA12337A (enExample)
PA (1) PA8523501A1 (enExample)
PE (1) PE20020277A1 (enExample)
PH (1) PH12001001922B1 (enExample)
PL (1) PL365133A1 (enExample)
PT (1) PT1305314E (enExample)
SK (1) SK572003A3 (enExample)
SV (1) SV2001000570A (enExample)
TN (1) TNSN01112A1 (enExample)
TW (1) TWI285643B (enExample)
UA (1) UA72631C2 (enExample)
UY (1) UY26854A1 (enExample)
WO (1) WO2002010171A1 (enExample)
YU (1) YU4703A (enExample)
ZA (1) ZA200301457B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371647B1 (en) * 1998-04-20 2005-07-13 Pfizer Inc. Pyridine-3-carboxylic acid derivatives and their use as intermediates
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
AU7269001A (en) 2002-02-13
DE60108398T2 (de) 2005-12-22
MX233602B (es) 2006-01-10
OA12337A (en) 2006-05-15
MA26931A1 (fr) 2004-12-20
MY117831A (en) 2004-08-30
PL365133A1 (en) 2004-12-27
YU4703A (sh) 2006-01-16
IL153226A0 (en) 2003-07-06
HRP20030061A2 (en) 2003-04-30
MXPA03000856A (es) 2003-06-06
KR100457937B1 (ko) 2004-11-20
BG107266A (bg) 2003-07-31
TWI285643B (en) 2007-08-21
ES2231521T3 (es) 2005-05-16
NZ523226A (en) 2003-07-25
HUP0302982A3 (en) 2005-01-28
DOP2001000217A (es) 2002-10-30
NO324220B1 (no) 2007-09-10
UA72631C2 (uk) 2005-03-15
KR20030016430A (ko) 2003-02-26
EE200300045A (et) 2004-12-15
CZ2003126A3 (cs) 2004-02-18
IN2002MU01649A (enExample) 2004-12-11
PH12001001922B1 (en) 2006-11-21
UY26854A1 (es) 2002-02-28
AP1400A (en) 2005-04-28
JP2004505087A (ja) 2004-02-19
DE60108398D1 (de) 2005-02-17
HUP0302982A2 (hu) 2003-12-29
EP1305314B1 (en) 2005-01-12
EP1305314A1 (en) 2003-05-02
WO2002010171A1 (en) 2002-02-07
ECSP034454A (es) 2003-03-10
EA200300079A1 (ru) 2003-06-26
SV2001000570A (es) 2002-09-03
CN1207297C (zh) 2005-06-22
GEP20053494B (en) 2005-04-25
AU2001272690B2 (en) 2005-12-08
BR0112734A (pt) 2004-08-10
EA004681B1 (ru) 2004-06-24
SK572003A3 (en) 2004-05-04
NO20030416D0 (no) 2003-01-27
DZ3364A1 (fr) 2002-02-07
NO20030416L (no) 2003-02-05
IS6626A (is) 2002-11-18
HK1055954A1 (en) 2004-01-30
PT1305314E (pt) 2005-04-29
AP2001002234A0 (en) 2001-09-30
PA8523501A1 (es) 2002-10-24
CN1444585A (zh) 2003-09-24
PE20020277A1 (es) 2002-05-11
ATE286901T1 (de) 2005-01-15
TNSN01112A1 (fr) 2005-11-10
CA2417264C (en) 2007-06-12
ZA200301457B (en) 2004-04-28
CA2417264A1 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
DE60319406D1 (de) Meso-substituierte porphyrine
ES2134804T3 (es) Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
UY27760A1 (es) Nuevos derivados de pirrolidinio.
AR030245A1 (es) Composiciones de gel que contienen metronidazol
EA199900532A1 (ru) Ингибиторы синтазы оксида азота
DOP2002000473A (es) Alquinos como inhibidores de metaloproteinasa de matriz
ECSP045286A (es) Indazoles sustituidos con una actividad anticancerosa
GB0121023D0 (en) Compound
CO5140092A1 (es) Metodo para mejorar el blanqueado de los dientes con peroxido
EA199700160A1 (ru) Производные индола в качестве антагонистов eaa
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
AR086573A2 (es) Derivados de 5-(piridin-3-il)-1-azabiciclo[3,2,1]octano y octeno, su preparacion y su aplicacion en terapeutica
ES2166128T3 (es) Mezcla fungicida.
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
BR0110902A (pt) Inibidores de mmp-9/mmp-2
CO5560584A2 (es) Nueva combinacion
EA200300079A1 (ru) Кристаллический терапевтический агент
ATE180485T1 (de) Nitrone verwendbar zum abfangen von freien radikalen
TR200001655T2 (tr) Ekinokandin türevleri, hazırlama yöntemi ve anti-fungal maddeler

Legal Events

Date Code Title Description
FB Suspension of granting procedure